PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
PolyPid announced it will present detailed analysis from the Phase 3 SHIELD II trial of D-PLEX(100) at the Surgical Infection Society Annual Meeting. The data showed a 64% relative risk reduction in patients with clinically significant wound infections compared to standard of care.
Key figures
- Drug Name
- D-PLEX(100)
- Phase Of Trial
- Phase 3
- Asepsis p value
- 0.0103
- Asepsis rrr percent
- 64
- Ssi incidence p value
- 0.0013
- Ssi incidence rrr percent
- 60
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.